Celldex director granted 26,000 stock options

Celldex Therapeutics director Cheryl Cohen received a grant of 26,000 stock options.

Rhea-AI Filing Summary

Celldex Therapeutics director Cheryl Cohen received a grant of 26,000 stock options. The non-qualified options give her the right to buy 26,000 shares of Celldex common stock at an exercise price of $34.09 per share. They were awarded under the company’s 2021 Omnibus Equity Incentive Plan.

After this grant, she holds 26,000 derivative securities directly, with the options exercisable starting June 25, 2027 and expiring on June 25, 2036. The filing reports no share sales or open-market purchases, indicating a routine equity compensation award rather than a market trade.

Insider Trade Summary

Grant/Award: 26,000 shares

Grant/Award 1 txn

Insider Cohen Cheryl

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Non-Qualified Stock Option (right to buy)	26,000	$0.00	$0.00

Holdings After Transaction: Non-Qualified Stock Option (right to buy) — 26,000 contracts (Direct)

Footnotes (1)

1. F1. Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

Key Figures

Option grant size: 26,000 options Exercise price: $34.09 per share Underlying shares: 26,000 shares +3 more

6 metrics

Option grant size 26,000 options Non-Qualified Stock Option grant on June 25, 2026

Exercise price $34.09 per share Exercise price for the 26,000 options

Underlying shares 26,000 shares Celldex common stock underlying the options

Post-grant derivative holdings 26,000 derivative securities Total options held following this transaction

Option exercise date June 25, 2027 Date options become exercisable

Option expiration date June 25, 2036 Final expiration of the option term

Key Terms

Non-Qualified Stock Option, 2021 Omnibus Equity Incentive Plan, Grant, award, or other acquisition, derivative securities

4 terms

Non-Qualified Stock Option financial

"Non-Qualified Stock Option (right to buy)"

A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.

2021 Omnibus Equity Incentive Plan financial

"Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan."

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

derivative securities financial

"total_shares_following_transaction: 26000.0000 derivative securities"

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Celldex (CLDX) report for Cheryl Cohen?

Celldex reported that director Cheryl Cohen received a grant of 26,000 non-qualified stock options. These options allow her to purchase Celldex common shares at a fixed exercise price under the company’s 2021 Omnibus Equity Incentive Plan.

How many Celldex stock options were granted to Cheryl Cohen?

Cheryl Cohen was granted 26,000 non-qualified stock options. Each option corresponds to one share of Celldex common stock, giving her the right to acquire up to 26,000 shares if she chooses to exercise the options in the future.

What is the exercise price of Cheryl Cohen’s new Celldex stock options?

The exercise price of the newly granted Celldex options is $34.09 per share. This means Cohen can buy Celldex common shares at $34.09 each upon exercise, regardless of the market price at that time, until the options expire.

When do Cheryl Cohen’s Celldex stock options expire?

Cheryl Cohen’s 26,000 non-qualified stock options expire on June 25, 2036. She may exercise them after the June 25, 2027 exercise date and before expiration, subject to the terms of Celldex’s 2021 Omnibus Equity Incentive Plan.

Did Cheryl Cohen buy or sell Celldex shares on the market in this Form 4?

No open-market purchases or sales were reported for Cheryl Cohen in this Form 4. The filing only shows an acquisition of 26,000 non-qualified stock options as an equity grant, which is a compensation event rather than a market trade.

Under which plan were Cheryl Cohen’s Celldex options granted?

The options were granted under Celldex’s 2021 Omnibus Equity Incentive Plan. This plan allows the company to grant equity-based awards, such as stock options, to directors and other eligible participants as part of their compensation package.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/29/2026 - 04:10 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cohen Cheryl

(Last) (First) (Middle)

C/O CELLDEX THERAPEUTICS, INC.

53 FRONTAGE ROAD, SUITE 202

(Street)

HAMPTON NEW JERSEY 08827

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Celldex Therapeutics, Inc. [ CLDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (right to buy)(1)	$34.09	06/25/2026(1)		A		26,000		06/25/2027	06/25/2036	Common Stock	26,000	$0	26,000	D

Explanation of Responses:

1. Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

	/s/ Sam Martin, attorney-in-fact for Cheryl L. Cohen	06/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)